The American Journal of Medicine
Volume 122, Issue 2 , Pages 107-108 , February 2009

Risk Stratification in Non-ST-segment Elevation Acute Coronary Syndromes: Troponin Alone Is not Enough

  • Philippe Gabriel Steg

      Affiliations

    • Inserm U-698, Université Paris 7 and Assistance Publique-Hôpitaux de Paris, Paris, France
    • ,
  • Gordon FitzGerald

      Affiliations

    • Center for Outcomes Research, University of Massachusetts, Worcester, Mass
    • ,
  • Keith A.A. Fox

      Affiliations

    • University of Edinburgh, Edinburgh, UK

References 

  1. Yan AT, Yan RT, Tan M, et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J. 2007;28:1072–1078
  2. de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005;26:865–872
  3. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835–842
  4. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291:2727–2733
  5. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med. 2003;163:2345–2353
  6. Yan AT, Yan RT, Tan M, et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med. 2007;167:1009–1016
  7. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292:2096–2104

 Funding: The GRACE registry is funded by a research grant from sanofi-aventis.

 Conflict of interest: Dr. Steg reports having received honoraria as speaker or consultant from Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, Endotis, GSK, Medtronic, MSD, Nycomed, sanofi-aventis, Servier, The Medicines Company. In addition, his institution has received a research grant from sanofi-aventis in the past 7 years. Dr. FitzGerald has no disclosures. Dr. Fox reports having received honoraria as speaker or consultant and research grants from Sanofi-aventis, GSK and Merck, Sharpe and Dohme.

 Authorship: All authors had access to the data and a role in writing the manuscript.

PII: S0002-9343(08)00972-8

doi: 10.1016/j.amjmed.2008.07.029

The American Journal of Medicine
Volume 122, Issue 2 , Pages 107-108 , February 2009

Article Tools

* Image Usage & Resolution